Researchers from the University of Wisconsin-Madison and University of California, San Diego collaborated on the study. They created a different form of CRISPR — called Mobile-CRISPRi — that sits on DNA instead of cutting it in two.
The method allows researchers to better assess how specific antibiotics target bacterial genes to inhibit pathogen growth.
“What that means is that you can now do studies on how antibiotics work directly in these pathogens,” study author Jason Peters, PhD, a professor of pharmaceutical sciences at UW Madison, said in a press release. “That could give us a better clue about how these drugs work in the different organisms and potentially what we can do to make them better.”
More articles on clinical leadership and infection control:
Flu vaccine linked to fewer hospital stays among COPD population
Travelers to Pakistan at risk of drug-resistant typhoid fever, CDC says
In EDs, children receive close to 7M antibiotic prescriptions every year
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.